Table 2.
Treatment characteristics between SBRT and CF-EBRT
| Variable | SBRT (n = 50) | CF-EBRT (n = 45) |
|---|---|---|
| Location, n (%) | ||
| Spine | 16 (32%) | 18 (40%) |
| Skull | 1 (2%) | 4 (9%) |
| Thorax | 10 (20%) | 7 (16%) |
| Pelvis | 15 (30%) | 8 (18%) |
| Upper extremity | 3 (6%) | 3 (6.7%) |
| Lower extremity | 5 (10%) | 5 (11%) |
| Median dose per fraction (range, Gy) | 9 (5-20) | 4 (1-4) |
| Gross tumor volume (range, cm3) | 35.55 (0.66-208.48) | 30.10 (3.13-259.57) |
| Planned tumor volume (range, cm3) | 93.55 (3.25-385.40) | 84.74 (14.36-874.60) |
| Biologic effective dose (range) | 108.00 (54.00-216.66) | 46.67 (29.33-93.33) |
| Systemic therapy before radiation, n (%) | ||
| Yes | 28 (56%) | 33 (73%) |
| No | 22 (44%) | 12 (27%) |
| Systemic therapy after radiation, n (%) | ||
| Yes | 39 (78%) | 38 (84%) |
| No | 11 (22%) | 7 (16%) |
| Time to symptom relief (range, weeks) | 2 (0-6) | 4 (0-7) |
CF-EBRT, conventional fractionated external beam radiation therapy; SBRT, stereotactic body radiation therapy.